Ipsen has secured exclusive global rights to develop and commercialize SIM0613, a promising antibody-drug conjugate targeting solid tumors, through a partnership with Simcere Zaiming.

Target Company Information

Ipsen S.A., a pioneering global biopharmaceutical company, has engaged in an exclusive licensing agreement with Simcere Zaiming for the global rights (excluding Greater China) to SIM0613, a next-generation antibody-drug conjugate (ADC) targeting the LRRC15 protein. This innovative agent is designed to enhance tumor penetration and demonstrate robust anti-tumor activity in solid tumors that exhibit significant unmet medical needs.

Further, the SIM0613 compound has exhibited promising preclinical efficacy and is expected to enter Phase I clinical trials in the latter half of 2026. The collaboration reinforces Ipsen's commitment to leading the oncology sector through transformative medical solutions.

Industry Overview

The biopharmaceutical industry in France has shown remarkable growth, especially in oncology, largely driven by innovation, research, and development. In recent years, a surge of investment into novel therapies and advanced drug delivery systems